Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest International AIDS Vaccine Initiative Stories

2009-09-22 10:32:11

U.S. scientists say they have created the first antigen that induces protective antibodies capable of blocking strains of the human immunodeficiency virus. Researchers at the University of Texas Health Science Center say their new chemically-activated antigen that can block infection of human cells by genetically diverse HIV strains could expedite development of an HIV vaccine. The HIV virus leads to the development of AIDS. The scientists, led by Professor Sudhir Paul, said the new antigen...

2009-09-21 10:17:00

ATLANTA, Sept. 21 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) (the "Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced that it has requested a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA) to discuss a proposed IND for GeoVax's therapeutic vaccine as a treatment for individuals...

2009-09-14 08:30:00

Atlanta to Serve as Stage for Premier Discussion on HIV Vaccine Development NEW YORK, Sept. 14 /PRNewswire-USNewswire/ -- The Global HIV Vaccine Enterprise (the Enterprise) today announced that the Center for AIDS Research at Emory University (CFAR) in Atlanta, Georgia will serve as Local Host of AIDS Vaccine 2010, the largest and most important global scientific conference focused on AIDS vaccine research. AIDS 2010 is to be held September 28 to October 1, 2010. This annual...

2009-09-04 10:42:38

After years of research, scientists in California say they have isolated two antibodies that prevent human immunodeficiency virus from becoming full-blown AIDS. The discovery could lead to a vaccine against AIDS, scientists at Scripps Research Institute in La Jolla said. Researchers collected blood samples from more than 1,800 people in Thailand, Australia and Africa who had been infected with HIV for at least three years without the infection developing into AIDS, Medpage reported Friday....

475f08bb9902eef879182fa3e2e09e1f
2009-09-03 13:50:00

Findings reveal an Achilles heel on the virus for AIDS vaccine researchers to exploit Researchers at and associated with the International AIDS Vaccine Initiative (IAVI), at The Scripps Research Institute, and at the biotechnology companies Theraclone Sciences and Monogram Biosciences have discovered two powerful new antibodies to HIV that reveal what may be an Achilles heel on the virus. They published their work in Science this week. Researchers will now try to exploit the newfound...

2009-08-26 11:04:00

ATLANTA, Aug. 26 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) (the "Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced that Robert McNally, Ph.D., president and chief executive officer, will present a company overview at the Rodman & Renshaw 11th Annual Healthcare Conference on Thursday, September 10, 2009 at 4:30 p.m. ET at the...

2009-08-11 09:39:30

U.S. scientists say conventional AIDS vaccine strategies shouldn't be the only plans of action considered in the fight against the disease. Researchers at the Yerkes National Primate Research Center, located at Emory University, said their proposal is based on studies involving simian immunodeficiency viruses in African non-human primates. Developing an effective AIDS vaccine has eluded scientists because the virus is tricky, said Dr. Guido Silvestri, a Yerkes affiliate scientist and director...

2009-08-05 09:08:00

ATLANTA, Aug. 5 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based HIV/AIDS vaccine development company, today announced updates on its ongoing and planned human clinical trials. "We have two main areas of focus for our HIV/AIDS vaccine - preventative and therapeutic," stated Robert McNally, Ph.D., Chief Executive Officer and President of GeoVax Labs, Inc. "The results of the early Phase 1 clinical work for the preventative version of the vaccine...

2009-07-20 02:00:00

New report finds first decline in HIV vaccine R&D investment in a decade CAPE TOWN, South Africa, July 20 /PRNewswire-USNewswire/ -- A new report on investment in HIV prevention research in 2008 finds that HIV vaccine research funding levels decreased for the first time since investment trends have been tracked. This may have been influenced by shifts in scientific priorities, the declining economy and competing priorities in the larger global health agenda. Despite this decrease,...

2009-07-01 12:44:03

Scientists said an HIV/AIDS vaccine developed at Canada's University of Western Ontario is ready for the first phase of human trials. Officials at Sumagen Co. Ltd., the manufacturer of the vaccine, said they have submitted an investigational new drug application to the U.S. Food and Drug Administration to begin Phase 1 human trials for its SAV001-H AIDS vaccine. The vaccine was developed by Professor Chil-Yong Kang who, with Sumagen, has completed safety and immunogenicity studies on...